(b) and (c) The claims for payment of Family Pension and Death-cum-Retirement Gratuity of deceased employees of Central Ordnance Depot, ii Cantt. and Ordnance Depot, Shakurbasti, are processed on priority. The procedural requirements of obtaining the death certificate of the deceased and identification of the legal heirs/next of kin of deceased employees sometimes result in unavoidable delays. The Depots, however, accord priority to all such cases.

Entitlement of the Chief Executive of a recognised Association

1648. SHRIMATI BIJOYA CHAKRAVARTY:
SHRI ANAND PRAKASH GAUTAM:
SHRI SARADA MOHANTY:

Will the PRIME MINISTER be pleased to state:

(a) whether the Chief Executive of a recognised association of employees of Government of India can hold (on posting/deputation in a coun- utside India; and

if so, the details thereof; if not, easons therefor?

THE MINISTER OF STATE IN THE ...STRY OF PERSONNEL, PUBLIC GRIEVANCES AND PENSIONS (SMT. MARGARET ALVA): (a) and (b) There are no instructions according to which the Chief Executive of a recognised association cannot hold office on posting/deputation in a country outside India.

Indigenous drug for cancer cure

1649. SHRI ASHOK NATH VERMA: Will the PRIME MINISTER be pleased to state:

(a) whether Government's attention has been drawn to news item appeared in Indian Express, Hyderabad on 10th August, 1991, captioned "Indigenous Drug for cancer cure";

(b) whether it is a fac tthat Technology for latest cancer drug has been developed by Indian company with the collaboration of the Government Laboratory;

(c) if so, what are the details thereof;

(d) whether it is also a fact that the drug is considered to be a major advancement of cancer chemotherapy;

(e) whether it is a fact that this drug is allowed for import;

(f) if so, what was the quantity imported during the last three years and what is the estimated demand;

(g) what is the price fixed for imported injection and at what price each injection is being sold; and

(h) whether it is a fact that indigenous injection is being offered at half the price?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (d) M/s. Cipla has in the past introduced some anti-cancer drugs in collaboration with National Laboratories. However details have not been received in this Department about the latest anti-cancer drug introduced by them.

(e) Yes. Sir.

(f) Details of import of formulations are not being monitored by this Department. Demand estimation for this drug has also not been done.

(g) and (h) None of the anti-cancer bulk drugs are price controlled under DPCO. However importers of anti-cancer formulations are required to charge not more than 50 per cent of the landed cost to meet distribution costs, transport costs and other charges inclusive of margins.

Multinational Drug Companies

1650. SHRI DHULESHWAR MEENA: Will the PRIME MINISTER be pleased to state:

(a) what are the names of multinational drug companies operating in India;

(b) whether it is a fact that most of these companies are importing drugs and finished medicines from their principals and associates;

(c) if so, names of the companies and names of drugs/finished medicines imported by each during the last two years, year-wise;

(d) whether it is a fact that all such information is being provided to Government under Form-6 which is obligatory; and

(e) names of the companies who did not submit Form-6 during 1989, 1990 and 1991 and what action has been taken against each of them?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) To the extent information is available, names of major multinational drug companies operating in India are given in the Annexure.

(b) and (c) This information is not monitored by this Department.

(d) Form-6 does not call for details regarding source of import, purchase etc.

(e) On the whole the response of industry in respect of furnishing the details as per form-6 has been lukewarm.

Usage of Imported and Indigenous raw materials

1651. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to state:

(a) whether Government have studied the usage of imported and indigenous raw materials by drug industry;

(b) if so. what is the position of Ten Major multinational drug companies like German Remedies, Glaxo, Hoechst, Wyeth, Sandoz etc.;

(c) what is the ratio between the usage of imported and indigenous raw material on overall basis;

(d) whether it is a fact that Government have ignored this aspect while taking a decision on the liberalisation of drug policy;

(e) whether it is a fact that Ratio Parameter has not been implemented so far;

(f) if so, the reasons therefor; and

(g) what steps have been taken in this direction?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) and (e) to (g) The Drug Policy 1986 provides that for any formulation activity, the value of overall consumption of imported bulk drugs should not be more than 50 per cent of the overall value of indigenously produced bulk drugs consumed. This parameter is being strictly implemented while considering the proposals of all Companies in the organised sector.

(d) The Drug Policy is still under review.

Revision of Assessment of the Price of Vitamin-C

1652. SHRI MOHD. KHALEELUR RAHMAN:

SHRI ASHOK NATH VERMA:

Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that discrepancy was found in the assessment of fixed assets which necessitated revision of BICP recommendations on the price of Vitamin-C recently;

(b) if so, what additions have been made by Government and on what account before revising the price;

(c) what was the period of which rate invoices were verified and what was the quantity of each input purchased at that rate;